Research & Development
MyMD Pharmaceuticals' Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
28 July 2021 - - Data from a comparative study conducted by Eurofins Discovery showing commonality between US-based clinical stage pharmaceutical company MyMD Pharmaceuticals, Inc's (NASDAQ: MYMD) lead clinical compound MYMD-1 and three FDA-approved JAK inhibitor drugs for the treatment of autoimmune and inflammatory diseases, the company said.

Janus Kinases are enzymes found in cells in the immune system that are critical for the cell signaling process. JAK inhibitors block the inflammatory signaling pathways, inhibiting the genes that trigger autoimmune processes.

The FDA has issued Boxed Warnings for one of the marketed JAK inhibitor drugs used in the comparative study.

The public was notified of serious side effects including an increased risk of blood clots in the lungs and death in rheumatoid arthritis patients taking a standard dose of the product.

In addition to JAK inhibition, MYMD-1 has shown efficacy as a selective inhibitor of TNF-α, a driver of chronic inflammation. MYMD-1 has also been shown to be effective in traversing the blood-brain barrier, a differentiator that can increase the drug's benefit to patients.

MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) is a clinical stage pharmaceutical company.

MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, and aging and longevity.

The company's second drug platform, Supera-CBD, is based on a novel (patent pending) synthetic derivative of cannabidiol that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase.

Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug.


Related Headlines